Erratum: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo (Journal of Bone and Mineral Research (2010) 25:12 (2633-2646) DOI:10.1002/jbmr.142);Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

Journal of Bone and Mineral Research

Volumn 25, Issue 12, 2010, Pages 2633-2646

  Chantry, Andrew D ^a   Heath, Debby ^a   Mulivor, Aaron W ^b   Pearsall, Scott ^b   Baud'Huin, Marc ^a   Coulton, Les ^a   Evans, Holly ^a   Abdul, Nicole ^a   Werner, Eric D ^b   Bouxsein, Mary L ^c   Key, Michelle L ^d   Seehra, Jasbir ^b   Arnett, Timothy R ^d   Vanderkerken, Karin ^e   Croucher, Peter ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Acceleron Pharma   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Activin A; Breast Cancer; Metastasis; Myeloma

Indexed keywords

ACTIVIN A; ACTIVIN RECEPTOR; PARAPROTEIN; PROTEIN ACTRIIA.MUFC; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE DISEASE; BONE LESION; BONE MASS; BONE METASTASIS; BONE MINERALIZATION; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MYELOMA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PROTEIN BLOOD LEVEL;

EID: 77957727888     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1705     Document Type: Erratum

References (47)

1. Mundy GR., Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-593.
2. Coleman RE., Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27: 165-176.
3. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol. 1989; 7: 1909-1914.
4. Mundy GR, Raisz LG, Cooper RA, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974; 291: 1041-1046.
5. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991; 88: 62-66.
6. Taube T, Beneton MN, McCloskey EV, et al. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992; 49: 192-198.
7. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol. 2000; 64: 121-129.
8. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335: 1785-1791.
9. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998; 16: 593-602.
10. Kanis JA, McCloskey EV., Bisphosphonates in multiple myeloma. Cancer 88(12 Suppl). 2000; 3022-3032.
11. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001; 91: 1191-1200.
12. Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (3):C. 2002; D003188.
13. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98: 1735-1744.
14. Ling N, Ying SY, Ueno N, et al. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature. 1986; 321: 779-782.
15. Vale W, Rivier J, Vaughan J, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature. 1986; 321: 776-779.
16. Schwartz NB, Channing CP., Evidence for ovarian "inhibin": suppression of the secondary rise in serum follicle stimulating hormone levels in proestrous rats by injection of porcine follicular fluid. Proc Natl Acad Sci U S A. 1977; 74: 5721-5724.
17. Woodruff TK, Mather JP., Inhibin, activin and the female reproductive axis. Annu Rev Physiol. 1995; 57: 219-244.
18. Feijen A, Goumans MJ, van den Eijnden-van Raaij AJ., Expression of activin subunits, activin receptors and follistatin in postimplantation mouse embryos suggests specific developmental functions for different activins. Development. 1994; 120: 3621-3637.
19. Tuuri T, Eramaa M, Hilden K, et al. The tissue distribution of activin beta A- and beta B-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development. J Clin Endocrinol Metab. 1994; 78: 1521-1524.
20. Zhang L, Deng M, Parthasarathy R, et al. MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration. Mol Cell Biol. 2005; 25: 60-65.
21. Munz B, Smola H, Engelhardt F, et al. Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair. EMBO J. 1999; 18: 5205-5215.
22. Chen YG, Lui HM, Lin SL, et al. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood). 2002; 227: 75-87.
23. Ogawa Y, Schmidt DK, Nathan RM, et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem. 1992; 267: 14233-14237.
24. Ikenoue T, Jingushi S, Urabe K, et al. Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem. 1999; 75: 206-214.
25. Gaddy-Kurten D, Coker JK, Abe E, et al. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology. 2002; 143: 74-83.
26. Eijken M, Swagemakers S, Koedam M, et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. Faseb J. 2007; 21: 2949-2960.
27. Fuller K, Bayley KE, Chambers TJ., Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Commun. 2000; 268: 2-7.
28. Oue Y, Kanatani H, Kiyoki M, et al. Effect of local injection of activin A on bone formation in newborn rats. Bone. 1994; 15: 361-366.
29. Perrien DS, Akel NS, Edwards PK, et al. Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology. 2007; 148: 1654-1665.
30. Bonewald LF, Mundy GR., Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res (250). 1990; 261-276.
31. Pearsall RS, Canalis E, Cornwall-Brady M, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A. 2008; 105: 7082-7087.
32. Leto G, Incorvaia L, Badalamenti G, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006; 23: 117-122.
33. Arnett TR, Gibbons DC, Utting JC, et al. Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol. 2003; 196: 2-8.
34. Radl J, De Glopper ED, Schuit HR, et al. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol. 1979; 122: 609-613.
35. Vanderkerken K, Asosingh K, Willems A, et al. The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med. 2005; 113: 191-205.
36. Glatt V, Canalis E, Stadmeyer L, et al. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res. 2007; 22: 1197-1207.
37. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
38. Vanderkerken K, Asosingh K, Croucher P, et al. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003; 194: 196-206.
39. Ottewell PD., 2008. Breast cancer cells cause a reduction in osteoblast number-an early event in the development of osteolytic bone lesions. VII International Meeting on Cancer Induced Bone Disease, Heriot Watt University, Edinburgh, Scotland, 29 June-2 July, 2008.
40. Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010.
41. Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010; 46: 1082-1088.
42. Ogino H, Yano S, Kakiuchi S, et al. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res. 2008; 14: 660-667.
43. Croucher PI, DeHendrik R, Parry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreases osteolysis, tumour burden and angiogenesis, and increased survival. J. Bone Miner. Res. 2003; 18: 2003; 482-492.
44. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma. Cancer Res. 2003; 63: 287-289.
45. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 2001; 61: 4432-4436.
46. Daubine F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007; 99: 322-330.
47. Li X, Pennisi A, Yaccoby S., Role of decorin in the antimyeloma effects of osteoblasts. Blood. 2008; 112: 159-168.